Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) generates frequent news through its work as a biopharmaceutical company focused on cardiovascular indications and diseases with unmet need. Company press releases and Form 8‑K filings highlight developments around its IL‑1 pathway franchise, including the commercial performance of ARCALYST (rilonacept) and the clinical progress of investigational monoclonal antibodies KPL‑387 and KPL‑1161.
News items commonly cover quarterly and annual financial results, where Kiniksa reports ARCALYST net product revenue, trends in prescriber adoption, and changes in guidance for expected ARCALYST net product revenue. These updates often include commentary on the uptake of IL‑1α and IL‑1β inhibition in recurrent pericarditis, the proportion of multiple‑recurrence patients on ARCALYST therapy, and the average duration of treatment.
Investors following KNSA news also see regular clinical and regulatory milestones. Kiniksa has announced the initiation and design of a Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, Phase 1 data supporting a monthly dosing profile, and the U.S. FDA’s Orphan Drug Designation for KPL‑387 for the treatment of pericarditis. Additional updates describe preclinical or IND‑enabling activities for KPL‑1161, which has a target profile of quarterly subcutaneous dosing.
Corporate and investor‑relations announcements form another key part of the KNSA news flow. The company frequently issues notices about upcoming and completed presentations at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, and other biopharma‑focused events. These communications typically reference webcasts and replays available through Kiniksa’s investor channels.
By monitoring this news stream, readers can track how Kiniksa manages ARCALYST commercialization, advances its IL‑1R1‑targeted pipeline, and updates its financial outlook. The KNSA news page on Stock Titan aggregates these releases so investors and observers can review earnings announcements, trial updates, regulatory designations, and conference participation in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.